Biology Reference
In-Depth Information
16. O'Driscoll M, Jeggo PA. The role of double-strand break repair:
insights from human genetics.
Nat Rev Genet
2006;
7
:45
38. Xiao Z, Xue S, Sowin TJ, Zhang H. Differential roles of checkpoint
kinase 1, checkpoint kinase 2, and mitogen-activated protein
kinase-activated protein kinase 2 in mediating DNA damage-
induced cell cycle arrest: implications for cancer therapy.
Mol
Cancer Ther
2006;
5
:1935
54.
17. Andreassen P, Ho G, D'Andrea A. DNA damage responses and
their many interactions with the replication fork.
Carcinogenesis
2006;
27
:883
e
92.
18. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemo-
sensitization versus chemoprotection.
Nat Rev Cancer
2004;
4
:
216
e
43.
39. Rodriguez-Bravo V, Guaita-Esteruelas S, Salvador N, Bachs O,
Agell N. Different S/M checkpoint responses of tumor and non
tumor cell lines to DNA replication inhibition.
Cancer Research
2007;
67
:11648
e
25.
19. Zhou BB, Sausville EA. Drug discovery targeting Chk1 and Chk2
kinases.
Prog Cell Cycle Res
2003;
5
:413
e
56.
40. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN.
The radiosensitizing agent 7-hydroxystaurosporine (UCN-01)
inhibits the DNA damage checkpoint kinase hChk1.
Cancer Res
2000;
60
:2108
e
21.
20. Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in
response to DNA damage.
Curr Opin Cell Biol
2001;
13
:738
e
47.
21. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the
checkpoint kinase 1/cell division cycle 25A pathway abrogates
ionizing radiation-induced S and G
2
checkpoints.
Proc Natl Acad
Sci USA
2002;
99
:14795
e
12.
41. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA,
O'Connor PM. UCN-01: a potent abrogator of G
2
checkpont
function in cancer cells disrupted with p53.
J Natl Cancer Inst
1996;
88
:956
e
800.
22. Sorensen CS, Syljuasen RG, Falck J, et al. Chk1 regulates the S
phase checkpoint by coupling the physiological turnover and
ionizing radiation-induced accelerated proteolysis of Cdc25A.
Cancer Cell
2003;
3
:247
e
65.
42. Russell KJ, Wiens LW, Demers GW, Galloway DA, Plon SE,
Gondine M. Abrogation of the G
2
checkpoint results in differ-
ential radiosensitization of G
1
checkpoint-deficient and G
1
checkpoint-competent cells.
Cancer Res
1995;
55
:1639
e
58.
23. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human
Cdc25A in response to DNA damage.
Science
2000;
288
:1425
e
42.
43. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, et al. Inhibition of
ATM and ATR kinase activities by the radiosensitizing agent,
caffeine.
Cancer Res
1999;
59
:4375
e
9.
24. Mailand N, Podtelejnikov AV, Groth A, et al. Regulation of G(2)/
M events by Cdc25A through phosphorylation-dependent
modulation of its stability.
EMBO J
2002;
21
:5911
e
82.
44. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in
the DNA damage-induced phosphorylation of p53.
Genes Dev
1999;
13
:152
e
20.
25. Peng CY, Graves PR, Thoma RS, et al. Mitotic and G2 checkpoint
control: regulation of 14-3-3 protein binding by phosphorylation
of Cdc25C on serine-216.
Science
1997;
277
:1501
e
7.
45. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A,
O'Connell MJ. Inhibition of Chk1-dependent G2 DNA damage
checkpoint radiosensitizes p53 mutant human cells.
Oncogene
2001;
20
:7453
e
5.
26. Dalal SN, Schweitzer CM, Gan J, DeCaprio JA. Cytoplasmic
localization of human cdc25C during interphase requires an
intact 14-3-3 binding site.
Mol Cell Biol
1999;
19
:4465
e
79.
27. Yang J, Winkler K, Yoshida M, Kornbluth S. Maintenance of G2
arrest in the Xenopus oocyte: a role for 14-3-3-mediated inhibition
of Cdc25 nuclear import.
EMBO J
1999;
18
:2174
e
63.
46. Luo Y, Rockow-Magnone SK, Joseph MK, et al. Abrogation of G
2
checkpoint specifically sensitize p53 defective cells to cancer
chemotherapeutic agents.
Anticancer Res
2001;
21
:23
e
83.
28. Zachos G, Rainey MD, Gillespie DA. Chk1-deficient tumour cells
are viable but exhibit multiple checkpoint and survival defects.
EMBO J
2003;
22
:713
e
8.
47. Luo Y, Rockow-Magnone SK, Kroeger PE, et al. Blocking Chk1
expression induces apoptosis and abrogates the G2 checkpoint
mechanism.
Neoplasia
2001;
3
:411
e
23.
29. Gatei M, Sloper K, Soerensen C, et al. Ataxia-telangiectasia-
mutated (ATM) and NBS1-dependent phosphorylation of Chk1
on Ser-317 in response to ionizing radiation.
e
9.
48. Chen Z, Xiao Z, Chen J, Ng SC, et al. Human Chk1 expression is
dispensable for somatic cell death and critical for sustaining G
2
DNA damage checkpoint.
Mol Cancer Ther
2003;
2
:543
e
J Biol Chem
8.
49. O'Connor MJ, Martin NMB, Smith GCM. Targeted Cancer ther-
apies based on the inhibition of DNA strand break repair.
Oncogene
2007;
26
:7816
e
11.
30. Xiao Z, Chen Z, Gunasekera AH, et al. Chk1 mediates S and G2
arrests through Cdc25A degradation in response to DNA-
damaging agents.
J Biol Chem
2003;
278
:21767
2003;
278
:14806
e
24.
50. Tenzer A, Pruschy M. Potentiation of DNA-damage-induced
cytotoxicity by G2 checkpoint abrogators.
Curr Med Chem Anti-
cancer Agents
2003;
3
:35
e
73.
31. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control
and cancer.
Cancer Cell
2003;
3
:421
e
9.
32. Ahn J, Urist M, Prives C. The Chk2 protein kinase.
DNA Repair
2004;
3
:1039
e
46.
51. Kawabe T. G2 checkpoint abrogators as anticancer drugs.
Mol
Cancer Ther
2004;
3
:513
e
47.
33. Falck J, Mailand N, Syljuasen RG, et al. The ATM-Chk2-Cdc25A
checkpoint pathway guards against radioresistant DNA synthesis.
Nature
2001;
410
:842
e
9.
52. Zhou BB, Anderson HJ, Roberge M. Targeting DNA checkpoint
kinases in cancer therapy.
Cancer Biol Ther
2003;
2
:S16
e
22.
53. Prudhomme M. Combining DNA damaging agents and check-
point 1 inhibitors.
Curr Med Chem Anticancer Agents
2004;
4
:435
7.
34. Takai H, Naka K, Okada Y, et al. Chk2-deficient mice exhibit
radioresistance and defective p53-mediated transcription.
EMBO
J
2002;
21
:5195
e
e
8.
54. Prudhomme M. Novel checkpoint 1 inhibitors.
Rec Patents Anti-
cancer Drug Disc
2006;
1
:55
e
205.
35. Zaugg K, Su Y-W, Reilly PT, et al. Cross-talk between Chk1 and
Chk2 in double-mutant thymocytes.
Proc Natl Acad Sci, USA
2007;
104
:3805
e
68.
55. Tao Z-F, Lin N- H. Chk1 inhibitors for novel cancer treatment.
Anticancer Agents Med Chem
2006;
6
:377
e
88.
56. Janetka JW, Ashwell S, Zabludoff S, Lyne P. Inhibitors of
Checkpoint kinases: From discovery to the clinic.
Curr Opin Drug
Disc Dev
2007;
10
:473
10.
36. Niida H, Katsuno Y, Banerjee B, Hande MP, Nakanishi M. Specific
role of Chk1 phosphorylations in cell survival and checkpoint
activation.
Mol Cell Biol
2007;
27
:2572
e
e
81.
37. Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J.
The relationship of premature mitosis to cytotoxicity in response
to checkpoint abrogation and antimetabolite treatment.
Cell Cycle
2006;
5
:1983
86.
57. Arrington KL, Dudkin VY. Novel inhibitors of checkpoint kinase
1.
Chemmedchem
2007;
2
:1571
e
e
85.
58. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1
in cancer therapeutics.
Clin Cancer Res
2007;
13
:1955
e
e
8.
e
60.
